Your session is about to expire
← Back to Search
Ladiratuzumab Vedotin + Pembrolizumab for Advanced Cancers
Study Summary
This trial will study a new cancer drug to see if it is effective and what side effects it may cause.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Small cell lung cancer (Parts A and B)You must have advanced stage cancer.You have only received one type of chemotherapy for advanced stage cancer.This applies to all groups of people being considered.You must have had your disease get worse during or after receiving chemotherapy with a certain type of medication called platinum-based systemic chemotherapy for extensive stage disease.You have a measurable disease as determined by the doctor, and you have a good ability to perform daily activities.You have advanced or metastatic non-small cell lung cancer and have seen your disease get worse after receiving certain types of treatments. You have also received specific types of chemotherapy and immunotherapy.You have prostate cancer that has spread and no more than one prior treatment with certain types of medication. You must not have certain genetic mutations or recent radiotherapy.You have a history of a certain type of lung disease.You have a measurable disease that can be assessed by the investigator using specific guidelines.You have advanced esophageal cancer that cannot be removed by surgery, and you have tried one type of strong medicine for your cancer.If you have stomach or gastroesophageal junction cancer that cannot be removed with surgery and has spread, you must have already tried a specific type of chemotherapy and your cancer must have gotten worse despite that treatment. If you have a certain protein called HER2 in your cancer, you must have already tried a treatment that targets that protein. You should not have tried more than one type of chemotherapy for your advanced cancer. You may have already tried a treatment that works by blocking a certain protein, unless it was not safe for you to do so.You must have a confirmed diagnosis of skin melanoma, and not have mucosal, acral, or uveal melanoma. Your melanoma should be at an advanced stage and have continued to grow after anti-PD(L)1 treatment. If your melanoma has a specific genetic mutation, you should have already received certain medications.You have another cancer that is growing, or you had cancer in the past 3 years.You have active brain or spinal cord lesions.Criterion: For people with head and neck cancer, the cancer must be inoperable and have either come back in the same place or spread to other parts of the body. The cancer must have gotten worse during or after previous treatment with medicines, including platinum-containing drugs. If the cancer came back within 6 months of receiving platinum therapy as part of a combined treatment, only one round of chemotherapy is allowed. Prior treatment with anti-PD(L)1 therapy is allowed unless it's not recommended for the participant.You have an ECOG performance score of 0 or 1.For this group, you must have extensive stage small cell lung cancer and your disease must have gotten worse after getting chemotherapy. You should have only had one round of chemotherapy for this stage of cancer and you may have had a type of immunotherapy called anti-PD(L)1 before.You have not had any cancer treatment within the past 3 weeks, except for hormonal therapy to prevent cancer from spreading.You are currently experiencing serious side effects from a previous treatment.You have moderate or severe ongoing numbness or weakness in your hands or feet.
- Group 1: Part B: Non-randomized LV monotherapy
- Group 2: Part A: Non-randomized LV monotherapy
- Group 3: Part C - Arm 3: Randomized LV combination therapy
- Group 4: Part C - Arm 1: Randomized LV monotherapy
- Group 5: Part C - Arm 2: Randomized LV combination therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still availability for participants in this clinical trial?
"Affirmative. Clinicaltrials.gov portrays that this clinical trial, originally posted on October 9th 2019, is now recruiting participants. A total of 264 patients should be recruited from 23 different medical centres."
How many individuals have enrolled in this research initiative?
"Affirmative. According to the information hosted on clinicaltrials.gov, this medical trial is actively accepting participants and was first posted October 9th 2019 before being updated most recently October 28th 2022. 264 patients need to be recruited from 23 different sites for this study."
What is the geographic scope of this scientific evaluation?
"Presently, 23 medical centres are offering this clinical trial. Of those locations, Decatur, Jacksonville and Chicago can be found in the list. It is recommended that potential participants join a location close to them to reduce travel burdens."
Could you provide information on the prior experiments that have been conducted utilizing ladiratuzumab vedotin?
"Presently, there are 5 active clinical trials for ladiratuzumab vedotin. Not one of these experimental protocols is in Phase 3 yet. Most studies take place in Saint Louis, Missouri; however, 236 different locations across the nation have some form of trial running related to this drug therapy."
Is ladiratuzumab vedotin a secure treatment option for individuals?
"Our research team has assessed the safety of ladiratuzumab vedotin to be a 2 due to its Phase 2 designation. This implies some existing data pertaining to safety, but no evidence yet regarding efficacy."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Average response time
- < 1 Day
Most responsive sites:
- Joe Arrington Cancer Research and Treatment Center: < 24 hours
Share this study with friends
Copy Link
Messenger